
|Videos|April 16, 2022
WATCH: A paradigm shift in the management of TED
Author(s)Andrew G. Lee, MD
Andrew Lee, MD, and Elizabeth Fortin, MD, discuss a paradigm shift in the treatment of thyroid eye disease with the new FDA approved medicine for managing TED.
Advertisement
In this week's discussion, Andrew Lee, MD, and Elizabeth Fortin, MD, disucss Teprotumumab, the first and only FDA approved medicine to treat thyroid eye disease (TED). They talk about the impact the drug can have on patients, cost considerations and how to use the treatment in the clinic.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial
2
Retina Society 2026: SOL-1 shows intravitreal axitinib hydrogel superior to aflibercept in wet AMD
3
Retina Society 2026: Ocular syphilis, HIV co-infection, and RPR titers
4
Retina Society 2026: How blood biomarkers may predict GA speed
5









